Brind.

FDA review is pending for cemdisiran submission from Regeneron Pharmaceuticals.

1 report, 1 independent Updated Aug 26

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Regeneron Pharmaceuticals

Keep exploring

The entities involved

FDA
- The FDA (Q11200607) and the Food Safety and Standards Authority of India (Q5465383) are involved in a new development regarding the governance of inspections.14:06
- FDA conducted surprise raids and inspections in Bihar state, directed by state government officials.14:06
Regeneron Pharmaceuticals
American pharmaceutical company
- Parabilis Medicines debuted on Nasdaq, achieving IPO haul surpassing Moderna's, while its product received FDA fast-track designation. Regeneron also acquired shares.Sat 13:46

Related events

Arise is seeking FDA approval for a drug as of October 7, 2026.Oct 7
Generic medicine services are seeking approval for launch from the FDA.Sep 28
Inventiva seeks FDA approval for lanifibranor in the U.S. market.Sep 2
The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.Jun 7
Beren Therapeutics' medicine is under FDA review, coinciding with a CNS meeting held in Montréal, Canada.Oct 15

Coverage

Newest first; wire copies grouped

Aug 26GlobeNewswireRegeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints,